•  
  •  
 

The Thai Journal of Pharmaceutical Sciences

Abstract

Background: Celecoxib, a model anti-inflammatory drug, used in the management of arthritis exhibits limited oral bioavailability and slow onset of action due to its poor solubility. Objective: The present study explores a mesoporous drug delivery of celecoxib to investigate the efficacy of its antiarthritic activity in animal models, and develops a low-oral dose therapy. Materials and Methods: The solvent evaporation method was employed for the preparation of mesoporous delivery of celecoxib, using Syloid®, and Neusilin®, at a molar ratio of silica/ drug 1:2.5. The formulations were characterized for drug loading, in vitro drug release, and material structure characteristics and bone mineral affinity. An in vivo study of the formulation was conducted on a diseased rat model. Investigation on hematological parameters, bone deformation through X-ray, and bone histopathology on the arthritic animals were conducted after oral administration of mesoporous celecoxib for 28 days. Histopathology studies of the liver and spleen were carried out as a measure of safety assessment of the new delivery of celecoxib. Results: The solvent evaporation method could yield 95–97% loading of celecoxib in the pores of silicas with significant enhancement in the dissolution efficiency of celecoxib. The formulations exhibited high bone mineral affinity compared to pure drugs. In vivo studies revealed a remarkable recovery of the cartilage over 28 days of treatment. The efficacy and safety of the mesoporous delivery of celecoxib were confirmed from the histopathology studies. Conclusion: The proposed delivery of celecoxib was found to be beneficial in the treatment of arthritis and the findings encourage its application.

DOI

10.56808/3027-7922.2995

Download

Plum Print visual indicator of research metrics
PlumX Metrics
  • Usage
    • Abstract Views: 27
    • Downloads: 26
see details

Share

COinS